Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

NCT07371104 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Ovarian Cancer

Interventions

DRUG: DWZ2501 (Olaparib 150mg)
DRUG: DWC202510 (Olaparib 150mg)

Sponsor

Daewoong Pharmaceutical Co. LTD.